Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Antibiotic Pipeline Profile: Balancing Broad Spectrum And Limited Use

Jul 05 2017

• By Bridget Silverman

Bacterias 3D rendering

Related Content

Cempra's Solithera Draws FDA Complete Response Letter On Liver Risks

Dec 29 2016

The First LPAD? Cempra May Try New Pathway For MRSA Antibiotic, Could Retrofit Solithromycin

Mar 07 2017

Melinta To Launch First Commercial Drug Baxdela Independently

Jun 22 2017

Tetraphase Bets On I.V. Eravacycline Rerun As Antibiotic Market Influx Looms

May 17 2017

Motif A Step Closer To Succeeding With Iclaprim After Phase III Success

Apr 18 2017

Nabriva Wants To Try A Different Approach To Antibiotic Stewardship

Apr 05 2017

Paratek Sees Broad Potential For Omadacycline After Second Phase III Win

Apr 04 2017

Keeping Track: US FDA Files Another Pfizer Cancer Biologic And TMC's New Antibiotic

Feb 24 2017

Plazomicin’s US Debut Pencilled In For 2018, Achaogen Now Searching For Ex-US Partner

Dec 15 2016

Shionogi Eyes ’17 US Cefiderocol Filing After New Results

Jan 17 2017

Related Companies

Merck & Co., Inc.

Melinta Therapeutics, Inc.

Melinta Therapeutics, Inc.

Paratek Pharmaceuticals, Inc.

Nabriva Therapeutics plc.

Achaogen, Inc.

Shionogi & Co. Ltd.

The Medicines Company

Wockhardt Limited

Motif Bio plc

Tetraphase Pharmaceuticals, Inc.

Additional Topics

US States Clinical Trials Research & Development Infectious Diseases BioPharmaceutical

More from Clinical Trials

More from R&D

Twitter feed RSS feed RSS feed

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.